📰 $MRNA Q4 & FY25 Outlook: 🔹 Q4 Results: • EPS: -$2.91 (Missed Est. -$2.68) • Revenue: $966M (Beat Est. $942.8M, -66% y/y) • COVID-19 Vaccine Rev: $923M (In Line) • Op. Loss: -$1.25B (Est. -$1.13B, vs. $6M profit y/y) • Cash & Equiv.: $1.93B (Est. $2.12B) 🔹 FY25 Guidance: • Revenue: $1.5B-$2.5B (Est. $2.43B) • CapEx: ~$400M (Est. $468.9M) • Cost Cuts: $1B by 2025-end • Cash & Inv. (Dec 31): $9.5B Q4 loss includes $200M in non-cash charges for manufacturing resizing.